Arbutus Biopharma Statistics
Total Valuation
ABUS has a market cap or net worth of $883.98 million. The enterprise value is $788.71 million.
| Market Cap | 883.98M |
| Enterprise Value | 788.71M |
Important Dates
The next estimated earnings date is Wednesday, August 5, 2026, before market open.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ABUS has 197.54 million shares outstanding. The number of shares has increased by 1.77% in one year.
| Current Share Class | 197.54M |
| Shares Outstanding | 197.54M |
| Shares Change (YoY) | +1.77% |
| Shares Change (QoQ) | +1.49% |
| Owned by Insiders (%) | 1.50% |
| Owned by Institutions (%) | 49.41% |
| Float | 121.37M |
Valuation Ratios
The trailing PE ratio is 5.36.
| PE Ratio | 5.36 |
| Forward PE | n/a |
| PS Ratio | 4.60 |
| Forward PS | 314.06 |
| PB Ratio | 3.34 |
| P/TBV Ratio | 3.38 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 4.91 |
| EV / Sales | 4.12 |
| EV / EBITDA | 5.08 |
| EV / EBIT | 5.09 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 54.26, with a Debt / Equity ratio of 0.02.
| Current Ratio | 54.26 |
| Quick Ratio | 54.00 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.03 |
| Debt / FCF | n/a |
| Interest Coverage | 1,803.41 |
Financial Efficiency
Return on equity (ROE) is 94.73% and return on invested capital (ROIC) is 55.57%.
| Return on Equity (ROE) | 94.73% |
| Return on Assets (ROA) | 49.18% |
| Return on Invested Capital (ROIC) | 55.57% |
| Return on Capital Employed (ROCE) | 57.01% |
| Weighted Average Cost of Capital (WACC) | 7.62% |
| Revenue Per Employee | $10.08M |
| Profits Per Employee | $8.46M |
| Employee Count | 19 |
| Asset Turnover | 0.97 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.33% in the last 52 weeks. The beta is 0.62, so ABUS's price volatility has been lower than the market average.
| Beta (5Y) | 0.62 |
| 52-Week Price Change | +42.33% |
| 50-Day Moving Average | 4.51 |
| 200-Day Moving Average | 4.45 |
| Relative Strength Index (RSI) | 44.06 |
| Average Volume (20 Days) | 2,788,267 |
Short Selling Information
The latest short interest is 17.11 million, so 8.66% of the outstanding shares have been sold short.
| Short Interest | 17.11M |
| Short Previous Month | 17.52M |
| Short % of Shares Out | 8.66% |
| Short % of Float | 14.10% |
| Short Ratio (days to cover) | 7.29 |
Income Statement
In the last 12 months, ABUS had revenue of $191.45 million and earned $160.72 million in profits. Earnings per share was $0.84.
| Revenue | 191.45M |
| Gross Profit | 171.04M |
| Operating Income | 155.09M |
| Pretax Income | 160.72M |
| Net Income | 160.72M |
| EBITDA | 155.14M |
| EBIT | 155.09M |
| Earnings Per Share (EPS) | $0.84 |
Balance Sheet
The company has $95.23 million in cash and $3.91 million in debt, with a net cash position of $91.32 million or $0.46 per share.
| Cash & Cash Equivalents | 95.23M |
| Total Debt | 3.91M |
| Net Cash | 91.32M |
| Net Cash Per Share | $0.46 |
| Equity (Book Value) | 260.18M |
| Book Value Per Share | 1.32 |
| Working Capital | 271.91M |
Cash Flow
| Operating Cash Flow | -34.36M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 44,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -34.36M |
| FCF Per Share | -$0.17 |
Margins
Gross margin is 89.34%, with operating and profit margins of 81.01% and 83.95%.
| Gross Margin | 89.34% |
| Operating Margin | 81.01% |
| Pretax Margin | 83.95% |
| Profit Margin | 83.95% |
| EBITDA Margin | 81.03% |
| EBIT Margin | 81.01% |
| FCF Margin | n/a |
Dividends & Yields
ABUS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.77% |
| Shareholder Yield | -1.77% |
| Earnings Yield | 18.26% |
| FCF Yield | -3.90% |
Analyst Forecast
The average price target for ABUS is $5.12, which is 14.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.12 |
| Price Target Difference | 14.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 60.54% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABUS has an Altman Z-Score of 24.5 and a Piotroski F-Score of 6.
| Altman Z-Score | 24.5 |
| Piotroski F-Score | 6 |